Clinical Trials

Kite Reports Real-World Analysis Results of Tecartus (brexucabtagene autoleucel) for Relapsed/Refractory Mantle Cell Lymphoma

Kite Reports Real-World Analysis Results of Tecartus (brexucabtagene autoleucel) for Relapsed/Refractory Mantle Cell Lymphoma

Shots: The real-world analysis of Tecartus showed ORR (90%) which was similar to (...

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer at ASCO 2023

Gilead to Presents P-III (TROPiCS-02) Study Results of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breas...

Shots: The P-III study (TROPiCS-02) evaluating Trodelvy vs CT in a ratio (1:1) in...

AstraZeneca Reports Interim Analysis Results of Enhertu (trastuzumab deruxtecan) in the P-II Trial (DESTINY-PanTumor02) for HER2-Expressing Advanced Solid Tumors

AstraZeneca Reports Interim Analysis Results of Enhertu (trastuzumab deruxtecan) in the P-II Trial (DESTINY-PanTumor02) for HER2-E...

Shots: The interim analysis from an ongoing P-II trial evaluating Enhertu (5.4mg/k...

Dr. Reddy Reports the Completion of the P-I Study of DRL_TC, a Proposed Biosimilar of Tocilizumab for Rheumatoid Arthritis

Dr. Reddy Reports the Completion of the P-I Study of DRL_TC, a Proposed Biosimilar of Tocilizumab for Rheumatoid Arthritis

Shots: The P-I study evaluating PK & PD of proposed tocilizumab biosimilar DRL...

AstraZeneca Presents Reports P-III Trial (ADAURA) Results of Tagrisso (osimertinib) for Early-Stage EGFR-Mutated Lung Cancer at ASCO 2023

AstraZeneca Presents Reports P-III Trial (ADAURA) Results of Tagrisso (osimertinib) for Early-Stage EGFR-Mutated Lung Cancer at AS...

Shots: The P-III trial evaluating Tagrisso (80mg, qd) vs PBO in 682 patients with...

Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 2023

Jazz and Zymeworks Present P-IIb Trial (HERIZON-BTC-01) Results of Zanidatamab for HER2-Amplified Biliary Tract Cancers at ASCO 20...

Shots: The P-IIb trial evaluating zanidatamab (20mg/kg, IV, q2w) in 87 patients at...

Image